Publications by authors named "J Miclea"
Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial.
Francois Guilhot Françoise Rigal-Huguet Joëlle Guilhot Agnès-Paule Guerci-Bresler Frédéric Maloisel Jean-Michel Miclea
Leukemia
August 2021
Article Synopsis
- - The SPIRIT trial is a long-term study that compares the effectiveness of various treatments for chronic-phase chronic myeloid leukaemia (CML), involving 787 patients followed for an average of 13.5 years.
- - Overall and progression-free survival rates after 15 years were similar across four treatment groups, ranging from 80% to 87%, suggesting comparable effectiveness of different combinations.
- - The combination of imatinib with pegylated interferon alpha2a resulted in significantly better molecular response rates compared to imatinib alone, although toxicity led to treatment cessation for some patients.
Article Synopsis
- The JAK2 mutation is crucial for diagnosing myeloproliferative neoplasms (MPN), and while qPCR is common, this study evaluates the effectiveness of next-generation sequencing (NGS) for detecting these mutations.
- Analysis of 427 patient DNA samples revealed strong agreement between qPCR and NGS when allelic burdens exceeded 2%, but NGS was less sensitive for lower burdens, missing some with qPCR values between 0.1 and 1%.
- The study identified various JAK2 variants through NGS, including a specific mutation that activates the JAK/STAT pathway, highlighting NGS as a reliable method to not only confirm mutations but also discover potentially significant new variants.
Article Synopsis
- High-dose chemotherapy with autologous stem cell transplantation is a common treatment for certain lymphoid malignancies, relying on the mobilization of hematopoietic stem and progenitor cells (HSPCs) from the bone marrow to the blood for collection via cytapheresis.
- Plerixafor, a new drug that alters the interaction between specific chemokines and their receptors, has been particularly beneficial for "poor mobilizers" who struggle to collect enough stem cells using traditional methods.
- A nationwide survey in France confirmed the effectiveness of plerixafor in improving stem cell mobilization, even for patients with limited response to other treatments, and showed that its usage was appropriate and did not
Background: High-dose chemotherapy (HDCT) is an effective salvage treatment of germ-cell tumors (GCTs) patients. In the first salvage setting, 30%-70% of patients may achieve durable remissions. Even when HDCT is administered as subsequent salvage treatment, up to 20% of patients may still be definitively cured.
View Article and Find Full Text PDFThe risk of developing Hodgkin lymphoma (HL) is increased in immunodeficiencies or during the treatment of some autoimmune diseases. The development of new therapeutic agents has highlighted the risk of unusual lymphoid proliferations, particularly classical HL (cHL). We report the clinicopathological findings of 13 cHL arising in patients treated for a primary haematological malignancy.
View Article and Find Full Text PDF